| Project/Area Number |
18K07972
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53010:Gastroenterology-related
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
Satoh Shinya 岡山大学, 医歯薬学総合研究科, 助教 (80333558)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | C/EBPα / リバビリン / GPAM / 中性脂肪量 / トリグリセリド合成 / 中性脂肪 / C/EBPa / 肝細胞 / 薬剤スクリーニング |
|---|
| Outline of Final Research Achievements |
We have previously demonstrated that anti-hepatitis C virus drug ribavirin reduces the amount of intracellular neutral lipids. In this study, we revealed that ribavirin-induced downregulation of C/EBPα and SREBP1c reduced the level of GPAM, which is one of the limiting enzymes of triglyceride synthesis, leading to the reduction in the intracellular neutral lipids. We also revealed the mechanism of the regulation of GPAM expression by C/EBPα, in which C/EBPα functions as the distal enhancer to maintain an open chromatin structure at C/EBPα binding regions in the GPAM genome.
Furthermore, by using the cell-based assay system monitoring the level of exogenously expressed C/EBPα protein, which was developed by us, and kinase screening library, we found mTOR-inhibitors reduced the level of C/EBPα protein, suggesting that mTOR contributes to sustaining C/EBPα protein level.
|
| Academic Significance and Societal Importance of the Research Achievements |
本研究で解明したトリグリセリド合成律速酵素であるGPAMの遺伝子発現制御機序では、C/EBPαが遠位のエンハンサーとして働き、GPAMゲノムDNAの構造変化を誘引し活性化することを初めて示した。
肝細胞での中性脂肪合成の亢進は脂肪肝、肝がんの発症リスクを高める。従って、本研究で得られた知見は中性脂肪合成を抑制する治療法や薬剤開発に貢献すると考えられ、肝病態発症の予防、改善に恩恵を与える。また、中性脂肪合成の亢進は、肝がんのみならず他組織でのがん発生、悪性化にも関わっており、組織の垣根を越えた抗がん作用の開発につながることが期待される。
|
